Coughing and wheezing can leave anyone wondering whether it is asthma or bronchitis at play. Both of these respiratory issues share symptoms but have different roots: one is a chronic condition, ...

It’s easy to blame swollen fingers on heat or a salty meal — but sometimes, your body might be alerting you to something far more serious.

You may find yourself reaching for tissues and a thermometer during the winter months, wondering what has you under the weather. As flu and cold season arrives, Michiganders face other illnesses like ...

It started out as a typical hot yoga class for Lavonda. The North Carolina resident was used to strenuous workouts, but on this day in 2008 she felt faint as she went through the sequence of poses.

Miami (November 11, 2025) – Men and women with chronic obstructive pulmonary disease (COPD), bronchiectasis, and nontuberculous mycobacterial (NTM) lung disease report differences in symptoms, mental ...

A study by CUNY SPH doctoral student Eslam Abousamra and Distinguished Professor Luisa N. Borrell found major disparities in antibiotic use across age groups, sex, race/ethnicity, education levels, ...

Prior exacerbations and greater symptom severity independently predicted future exacerbations in patients with bronchiectasis. Long-term macrolide proved beneficial not only for patients with frequent ...

MPR: What is non-cystic fibrosis bronchiectasis? Dr Addrizzo-Harris: Non-cystic fibrosis bronchiectasis is an abnormality of the airways in the lung where the airways become dilated, often permanently ...

GERD was significantly linked to an increased incidence of asthma and pneumonia, pulmonary fibrosis, COPD, lung cancer, interstitial lung disease, bronchiectasis, bronchitis, acute lung injury, ...

Treatment with brensocatib 10 mg and 25 mg significantly reduced the annual rate of pulmonary exacerbations in patients with NCFB. The Food and Drug Administration (FDA) has approved Brinsupri ™ ...

Brinsupri (brensocatib) is a new oral medicine approved to treat a long-term lung disease known as non-cystic fibrosis bronchiectasis (NCFB) in adults and children ages 12 or older. It works by ...

With a landmark U.S. approval Tuesday, Insmed is making waves with a new class of drug that’s also the first to be green lit in the chronic lung disease bronchiectasis. The FDA has signed off on ...